Clinical Investigators Urge FDA Approval of Deramiocel for Duchenne Muscular Dystrophy
A group of 28 physician-scientists who participated in Capricor's HOPE-3 trial have written to the FDA advocating for the approval of Deramiocel.
Stocks · News reference
Capricor Therapeutics Posts Commercial Job Openings Ahead of FDA Decision
Capricor Therapeutics has listed new senior-level commercial and patient services roles, signaling potential preparations for the commercial launch of its lead product candidate, Deramiocel.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Analyst Price Target for Capricor Therapeutics Raised to $27
Analysts have increased the 12-month price target for Capricor Therapeutics, Inc. to $27, reflecting a potential upside based on recent market data.
Capricor Therapeutics to Report Third Quarter 2026 Financial Results on November 10
Capricor Therapeutics announced it will release its financial results for the third quarter ended September 30, 2026, on November 10, 2026.
Capricor Therapeutics shares are trading lower after the company announced extension data from its ongoing HOPE-3 OLE study of Deramiocel on upper limb in Duchenne muscular dystrophy, which included 12-month and 24-month observations.
What's Going On With Capricor Therapeutics Stock Monday?
Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of its Nov 22 FDA PDUFA date.
Capricor Therapeutics Presents New Data From Ongoing HOPE-3 OLE Study For Its Lead Asset, Deramiocel, For Treatment Of Upper Limb Impairment In DMD, At 31st Annual Congress Of WMS In Hiroshima